-
1 Comment
Shenzhen Neptunus Bioengineering Co., Ltd is currently in a long term downtrend where the price is trading 9.6% below its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.2.
Shenzhen Neptunus Bioengineering Co., Ltd's total revenue rose by 10.4% to $11B since the same quarter in the previous year.
Its net income has dropped by 55.4% to $72M since the same quarter in the previous year.
Finally, its free cash flow fell by 6411.4% to $-616M since the same quarter in the previous year.
Based on the above factors, Shenzhen Neptunus Bioengineering Co., Ltd gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | SHE |
| CurrencyCode | CNY |
| ISIN | CNE000000X95 |
| Market Cap | 6B |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.41 |
| Dividend Yield | None |
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine tablets, chlorpheniramine maleate tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and provides value-added services for hospitals, medical institutions, and drug retail institutions and distributors. The company offers drugs in the fields of malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases, and multiple diseases, such as respiratory system and digestive system. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 1989 and is headquartered in Shenzhen, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 000078.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
